ANK3

Across TCGA pan-cancer cohorts, ANK3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANK3 data layer compared with 20 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANK3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANK3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where ANK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.722	0.407	.002	40	view →
CCRCC	OS	Tertile	All	1.000	0.540	.002	29	view →
UCEC	DFS	Median	All	0.967	0.845	.007	12	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANK3–PDAC (OS)

Open the PDAC breakdown →